ArticleThe Lancet. Neurology2021
The International Parkinson Disease Genomics Consortium Africa.
Article in The Lancet. Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions.Movement disorders : official journal of the Movement Disorder Society · 2022Pooled it
- Global research synergy: Advancing fundamental Parkinson's research through international collaboration.Journal of Parkinson's disease · 2026Review
- Bridging global diversity gaps in Parkinson disease research.Nature reviews. Neurology · 2026Review
- Early-Onset Parkinson's Disease: Unique Features and Management Approaches.Current neurology and neuroscience reports · 2025Review
- Use of the visual analogue Parkinson's Disease Sleep Scale in Nigeria.Equity neuroscience · 2025Article
- A Global Perspective ofGenes · 2024Review
- No causal relationship between ankylosing spondylitis and Parkinson's disease: Insights from Mendelian randomization studies.Heliyon · 2024Article
- The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson's disease.NPJ Parkinson's disease · 2024Article
- Exploring the role of underrepresented populations in polygenic risk scores for neurodegenerative disease risk prediction.Frontiers in neuroscience · 2024Article
- The Landscape of Monogenic Parkinson's Disease in Populations of Non-European Ancestry: A Narrative Review.Genes · 2023Review
- Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson's disease.NPJ Parkinson's disease · 2023Review
- Article
- Parkinson's genetics research on underrepresented AfrAbia populations: current state and future prospects.American journal of neurodegenerative disease · 2023Review
- APOE E4 is associated with impaired self-declared cognition but not disease risk or age of onset in Nigerians with Parkinson's disease.NPJ Parkinson's disease · 2022Article
- Editorial: Genetic and molecular diversity in Parkinson's disease.Frontiers in aging neuroscience · 2022Article
- Mapping the Diverse and Inclusive Future of Parkinson's Disease Genetics and Its Widespread Impact.Genes · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.